Without the right patent strategy, drug developers risk losing investors and sacrificing commercial potential.

On this weeks episode of the Business of Biotech, David Craig, Cofounder, President, and CEO at Sarcomatrix, explains why the old biotech playbook breaks down in today’s funding environment and what ...

On this weeks episode of the Business of Biotech, Olivier Litzka, Partner at Andera Partners, talks about what it really takes for biotech companies to attract capital, stay focused, and survive the ...

Deciding whether a drug candidate should be developed as part of a combination or not should hinge on available evidence and ...

On this weeks episode of the Business of Biotech, Omar Khalil, Managing Director at Santé Ventures, describes forming and funding startups and early-stage biotech companies with a focus on clinical ...

Why did John Oyler, an American entrepreneur, decide to build a global biopharmaceutical company with roots in China? Ask the chairman, cofounder, and CEO of BeiGene that question and you’re going to ...

Industry Explorers Blaze On: A series of stories of longtime leaders, still active in the industry, sharing their historical perspectives on life sciences industry innovation. A consuming interest, ...

Life sciences companies operate at the leading edge of innovation, structuring high-value licensing, development, and outsourcing arrangements in a highly regulated environment. A persistent and often ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

Over the last decade, the discoveries and ensuing results from revolutionary cell and gene therapy research have led to the rapid growth of biotech companies taking these immunotherapy treatments into ...

For Boehringer Ingelheim’s (BI) first foray into biosimilars, the company went straight to the top, developing an interchangeable biosimilar for AbbVie’s Humira, one of the best-selling pharmaceutical ...

As the fentanyl epidemic rages on, opioid antagonist rescue agents like Narcan, Kloxxado, and Opvee have become omnipresent. Like defibrillators and EpiPens, advocates insist they should be available ...